ZEGFROVY (Sunvozertinib)

Inquire / Price
  • Model Number:
    RL3220250101
  • Brand Name:
    ZEGFROVY®/舒沃哲®
  • Origin:
    Original invention from China
  • Small Orders:
    Small batches also available
  • Tags:
Inquire Now Link

Poster
  • Details
  • Description
  • Packaging Size
    7t*2blister/Box
  • Strength
    150mg
  • Compositon
    Sunvozertinib
  • Treatment
    adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations
  • Form
    Tablet
  • Brand
    ZEGFROVY®/舒沃哲®
  • Quantity Unit
    14t/Box
  • Manufacturer
    Dizal Pharma, china

Sunvozertinib (DZD9008) is an oral, potent, irreversible, and selective EGFR TKI targeting EGFR exon20ins as well as EGFR sensitizing, T790M, and uncommon mutations with weak activity against wild-type EGFR.

Sunvozertinib is being developed by Dizal Pharmaceuticals, a joint venture between AstraZeneca and the Chinese Future Industry Investment Fund.

  • Sunvozertinib sold under the brand name 舒沃哲® in china.
  • Sunvozertinib sold under the brand name ZEGFROVY® in USA.

In August 2023, China’s National Medical Products Administration approved sunvozertinib for the treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations whose disease has progressed on or following platinum-based chemotherapy, based on data from the phase 2 WU-KONG6 trial (NCT05712902).

<FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations.>


Link

Poster

Top